Litcius/Paper detail

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Takashi Kadowaki, Joakim Isendahl, Usman Khalid, Sang Yeoup Lee, Tomoyuki Nishida, Wataru Ogawa, Kazuyuki Tobe, Toshimasa Yamauchi, Soo Lim

2022The Lancet Diabetes & Endocrinology307 citationsDOI

Topics & Concepts

MedicineSemaglutideOverweightType 2 diabetesDouble blindPlaceboObesityPopulationDiabetes mellitusRandomized controlled trialInternal medicineTraditional medicinePhysical therapyEndocrinologyAlternative medicineEnvironmental healthLiraglutidePathologyDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerBariatric Surgery and Outcomes